- Home
- SBCF vs ARQT Comparison
SBCF vs ARQT Comparison
Compare SBCF & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBCF
- ARQT
- Stock Information
- Founded
- SBCF 1926
- ARQT 2016
- Country
- SBCF United States
- ARQT United States
- Employees
- SBCF 1504
- ARQT N/A
- Industry
- SBCF Major Banks
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- SBCF Finance
- ARQT Health Care
- Exchange
- SBCF Nasdaq
- ARQT Nasdaq
- Market Cap
- SBCF 2.1B
- ARQT 1.7B
- IPO Year
- SBCF N/A
- ARQT 2020
- Fundamental
- Price
- SBCF $25.00
- ARQT $13.82
- Analyst Decision
- SBCF Buy
- ARQT Strong Buy
- Analyst Count
- SBCF 4
- ARQT 6
- Target Price
- SBCF $29.25
- ARQT $18.80
- AVG Volume (30 Days)
- SBCF 541.2K
- ARQT 2.0M
- Earning Date
- SBCF 07-24-2025
- ARQT 08-13-2025
- Dividend Yield
- SBCF 2.88%
- ARQT N/A
- EPS Growth
- SBCF 6.66
- ARQT N/A
- EPS
- SBCF 1.48
- ARQT N/A
- Revenue
- SBCF $506,381,000.00
- ARQT $212,819,000.00
- Revenue This Year
- SBCF $23.90
- ARQT $61.15
- Revenue Next Year
- SBCF $25.88
- ARQT $37.98
- P/E Ratio
- SBCF $16.89
- ARQT N/A
- Revenue Growth
- SBCF N/A
- ARQT 100.03
- 52 Week Low
- SBCF $21.36
- ARQT $7.86
- 52 Week High
- SBCF $31.68
- ARQT $17.75
- Technical
- Relative Strength Index (RSI)
- SBCF 47.31
- ARQT 50.73
- Support Level
- SBCF $25.26
- ARQT $12.97
- Resistance Level
- SBCF $26.83
- ARQT $13.84
- Average True Range (ATR)
- SBCF 0.58
- ARQT 0.61
- MACD
- SBCF -0.15
- ARQT 0.02
- Stochastic Oscillator
- SBCF 22.78
- ARQT 51.64
About SBCF Seacoast Banking Corporation of Florida
Seacoast Banking Corp of Florida is a holding company for Seacoast National Bank. The company provides integrated financial services including commercial and consumer banking, wealth management, and mortgage and insurance services to customers across Florida, and through mobile and online banking solutions. In addition, it provides services such as treasury management, brokerage and credit facilities.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.